Table 1.
Current prices for antiretrovirals in the USA, UK and low-income countries [8–11]
| Antiretroviral | Patent expiry | Price per person-year (US$)* | ||
|---|---|---|---|---|
| USA | UK | Global lowest | ||
| Nucleos(t)ide analogues | ||||
| Abacavir | Generic/2016 (Europe) | $7,236 | $2,778 | $123 |
| Lamivudine | Generic | $3,408 | $483 | $18 |
| Tenofovir | 2017–8 | $14,464 | $3,182 | $39 |
| Zidovudine/3TC | Generic | $10,536 | $1,107 | $46 |
| Abacavir/3TC | 2016 | $18,600 | $4,664 | $161 |
| Tenofovir DF/3TC | 2017–8 | not sold | not sold | $47 |
| Tenofovir DF/FTC | 2021 | $21,120 | $5,553 | $67 |
| Tenofovir DF/FTC/EFV | 2021 | $34,428 | $8,314 | $110 |
| Non-nucleosides | ||||
| Nevirapine | Generic | $7,776 | $1,825 | $28 |
| Efavirenz | Generic/2017 (USA) | $12,120 | $1,606 | $38 |
| Rilpivirine | 2021 | $12,900 | $3,120 | $40 |
| Etravirine | 2021 | $15,696 | $4,695 | $438 |
| Protease inhibitors | ||||
| Atazanavir | 2017–9 | $19,872 | $4,726 | $219 |
| Lopinavir/r | 2016 | $13,272 | $4,446 | $243 |
| Darunavir/r | 2017–19 | $19,584 | $4,648 | $658 |
| Integrase strand inhibitors | ||||
| Dolutegravir | 2027 | $20,484 | $7,768 | $600* |
| Raltegravir | 2025 | $18,540 | $7,347 | $973 |
| Elvitegravir | 2027 | $37,116 | $8,314 | No data |
*
Using a conversion rate of 1.3 US dollars to 1 UK pound.